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Abstract
Background: Association of leukoencephalopathy and atypical mycobacteriosis has been rarely reported. We present
a case that is relevant for its unusual presentation and because it may shed further light on the pathogenic mechanisms
underlying reversible encephalopathies.
Case report: We report the case of a Hispanic 64-year-old woman with cognitive decline and extensive
leukoencephalopathy. Magnetic resonance imaging revealed white-matter lesions with increased water diffusivity,
without blood–brain-barrier disruption. Brain biopsy showed tissue rarefaction with vacuolation, mild inflammation, few
reactive astrocytes and decreased aquaporin water-channel expression in the lesions. Six months later, she was diagnosed
with atypical mycobacterial pulmonary infection. Brain lesions resolved after antimycobacterial treatment.
Conclusion: We hypothesize leukoencephalopathic changes and vasogenic edema were associated with decreased
aquaporin expression. Further studies should clarify if reversible leukoencephalopathy has a causal relationship with
decreased aquaporin expression and atypical mycobacterial infection, and mechanisms underlying leukoencephalopathy
resolution after antimycobacterial treatment. This article may contribute to the understanding of pathogenic mechanisms
underlying magnetic resonance imaging subcortical lesions and edema, which remain incompletely understood.
Keywords: Reversible encephalopathy syndrome, PRES, Mycobacteriosis, Leukoencephalopathy, Vasogenic
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Background
Reversible leukoencephalopathy is characterized by head-
aches, seizures, vomiting, and confusion, associated with
extensive bilateral white-matter subcortical neuroimaging
abnormalities, suggestive of vasogenic edema without
infarction [1]. Most cases of reversible encephalopathy are
referred to as posterior reversible encephalopathy
syndrome (PRES), since white matter changes are more
prominent in the posterior cerebral regions. Brainstem,
cerebellum and other brain regions may also be affected
[2]. PRES has been associated with severe hypertension
(including eclampsia), renal dysfunction, infection, autoi-
mune disease, and immunosuppressant drug use [1–7].
The hallmark of PRES is reversible cerebral edema due
to blood–brain-barrier dysfunction [8]. Pathogenic
mechanisms underlying magnetic resonance imaging
(MRI) subcortical lesions and edema remains incom-
pletely understood.
Association of brain edema and mycobacteria has pre-
viously been reported in the setting of Mycobacterium
tuberculosis infection [9–15], and in one patient who
presented with acute disseminated encephalomyelitis
(ADEM) associated with Mycobacterium intracellulare
meningitis, who responded to high dose steroid pulse
therapy [16]. In all reported cases of mycobacterial infec-
tion associated with edema, underlying mechanisms
involved demyelination and inflammation. Association
of a non-demyelinating leukoencephalopathy and atypical
mycobacteriosis has not, to our knowledge, been previ-
ously reported.
We report neuroimaging and brain histology features of
a patient with extensive leukoencephalopathy with brain
edema and absence of demyelination, that resolved after
atypical mycobacterial pulmonary infection treatment.
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Case presentation
A Hispanic 64-year-old woman was admitted with head-
aches, vomiting and confusion. A month earlier, the pa-
tient presented with subacute new-onset headaches,
nausea, vomiting, gait impairment, and anorexia. There
was no history of fever, cough, abdominal pain, previous
medical disease or immunosuppressant drug use. Blood
pressure was normal. Physical examination was unre-
markable. Neurologic examination showed an unsteady
gait, without motor weakness or ataxia. Cognitive tests
showed a Mini-Mental Status Exam (MMSE) score of
18/30, impaired attention, executive functions, verbal
fluency and episodic memory (Table 1).
Brain MRI disclosed diffuse and symmetric confluent
nonenhancing white matter lesions, that were hyperin-
tense in T2/FLAIR images (Fig. 1a to d). Corresponding
apparent diffusion coefficients (ADC) maps suggested
vasogenic edema (Fig. 1f ). MRI angiography was unre-
markable (not shown). Multivoxel spectroscopy, dy-
namic susceptibility contrast (DSC) perfusion (T2*) and
dynamic contrast-enhanced (DCE) permeability (T1) did
not disclose relevant abnormalities (Fig. 1e, g and h).
Cerebrospinal fluid analysis showed a normal cell count
(4 cells/mm3), protein (32 mg/dL) and glucose (80 mg/dL)
levels, normal protein electrophoresis values, negative
oligoclonal bands and polymerase chain reaction for infec-
tious agents (including tuberculosis). Systemic evaluation
was negative for cancer, autoimmune diseases (Anti-nu-
clear antibodies = negative, Anti-neutrophil cytoplasmic
antibodies = negative), and infectious diseases. Thoracic
computed tomography (CT) showed nonspecific patchy
lung infiltrates. Blood laboratory tests were normal (i.e.
Erythrocyte sedimentation rate = 2 mm; C-reactive protein
= 1,3 mg/L; Leucocytes = 6,880/mm3). Electroencephalo-
gram EEG showed mild diffuse slowing and brief bursts of
diffuse delta waves. The patient underwent two brain
biopsies that showed tissue rarefaction with vacuolation,
very mild inflammatory cell and macrophage infiltrates, ab-
sence of demyelination, malignant cells or granulomas, and
no signs of tissue infarction or hemorrhagic changes
(Fig. 2a to j). Immunostaining showed scarce CD45+ lym-
phocytes and CD68+ macrophages, without axonal or
myelin damage, with few reactive astrocytes and low
aquaporin-4 staining in the lesion compared to the normal
surrounding areas. Aquaporin-1 staining was also reduced
in the lesion, less extensively than aquaporin-4.
The patient was treated initially with intravenous
methylprednisolone (1 g/day for three days), followed by
oral dexamethasone (10 mg/day) for six months. Clinical
and neurologic status and brain MRI remained un-
changed. Activities of daily living were impaired, with a
Functional Activity Questionnaire (FAQ) score of 25 and
MMSE score of 18. Whole body positron emission
tomography-computed tomography obtained at this point
revealed a hypermetabolic right pulmonary mass. Lesion
histology showed granulomas containing Mycobacterium
abscessus. The patient was treated with levofloxacin, clari-
thromycin and amycacin. Steroids were tapered and dis-
continued. A year later, cognitive functions and functional
status were improved (MMSE = 21; FAQ score = 10)
(Table 1), and brain MRI disclosed remarkable resolution
of white matter changes (Fig. 1i–l).
Conclusions
This report illustrates a case of leukoencephalopathy asso-
ciated with atypical pulmonary mycobacteriosis. Although
we cannot establish a cause-effect relationship of atypical
mycobacteriosis and leukoencephalopathy, lack of central
nervous system (CNS) granulomas and caseous necrosis,
lack neurological worsening following steroid therapy, and
improvement after antimycobacterial treatment suggest a
Table 1 Cognitive evaluations in a patient with reversible leukoencephalopathy before and after atypical mycobacteria treatment
Initial assessment Five months after initial
assessment (no mycobacterial
treatment)
Eighteen months after initial
assessment (one year of mycobaterial
treatment)
Mini Mental State Exam (MMSE) 18/30 18/30 22/30
Digit span (direct/indirect) 3 / 0 3 / 0 4 / 2
Short Memory Test with 10 items (incidental
memory / immediate memory / learning)*
3 / 7 / 8 4 / 1 / 1 5 / 7 / 8
Delayed Memory Test with 10 items
(after distraction) without / with hints*
6 (1) / 8 3 / 4 (3) 8 / 10
Verbal fluency (semantic / phonemic) 5 (animals) / 1 (letter P) 6 (animals) / 1 (letter P) 10 (animals) / 1 (letter P)
Clock-drawing test Disexecutive: distortion
of number placement
(4 points)
Disexecutive: crowding
numbers to one side (5 points)
More noticeable errors in hand/
number placement (8 points)
Functional Activity Questionnaire (FAQ) 25/30 10/30
Patient’s education: 4 Years
Legend: *Number of intrusions between brackets
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remote effect of the lung infection, causing the CNS
disorder.
Initial chest CT had initially shown nonspecific patchy
lung infiltrates, that could, retrospectively, indicate early
stage atypical mycobacterial infection. Additionally, the
patient presented remarkable, albeit partial, neurological
improvement after antimycobacterial treatment. There
was no response to steroid therapy, brain pathology
studies did not disclose inflammatory activity, and there
was absence of intra-thecal antibody production, render-
ing the possibility of an adaptative immune mechanism
(i.e. antibody or cell-mediated immune responses)
extremely unlikely. Steroid therapy may have contrib-
uted to worsening of the mycobacterial lung infection.
Mycobacteria are known to be highly immunogenic:
mycobacteria containing compounds are used in mouse
models of ADEM and Multiple Sclerosis, through activa-
tion of adaptative immunity [17, 18]. Mycobacteria also
activate the innate immune system, with production of
cytokines and inflammation mediators, such as nitric
oxide [19].
Mechanism of brain involvement in this case can be
inferred from imaging and pathology findings of tissue
edema with scarce reactive astrocytes, and reduced
aquaporin-4 and aquaporin-1 expression in the lesion,
compared to surrounding areas. Considering the lack of
evidence of adaptative immune response in the brain, we
speculate that activation of an innate-immune response
in the lung either by the mycobacteria or through a host
mediated response may have exerted a remote effect on
aquaporin expression in the brain, leading to interstitial
white matter edema. Alternatively, but less likely, anti-
mycobacterial agents may have exerted a direct action
reverting white matter lesions [20].
Few studies have evaluated pathological findings in
reversible encephalopathies [1, 2, 8, 21], and some
Fig. 1 Serial brain magnetic resonance imaging studies of a patient with reversible leukoencephalopathy. Brain magnetic resonance imaging (MRI).
Initial FLAIR images (a-d) show diffuse symmetrical confluent hyperintensities involving cerebral white matter, extending to the brainstem and cerebellar
white matter. Note mass effect evidenced by sulci, fissure and ventricle effacement (more remarkable considering patient’s age - 64 years old).
Corresponding white matter MR spectroscopy (e) (multivoxel, TE = 135 ms) demonstrates no definite metabolic changes. Apparent diffusion coefficients
(ADC) map (f) demonstrates diffusion facilitation, signaling vasogenic edema. There was no contrast enhancement (not shown) or significant changes
appreciated in color maps proportional to relative cerebral blood volume (rCBV) (g) obtained from a dynamic susceptibility contrast (DSC) perfusion (T2*)
study. Color maps proportional to wash in rate (h) obtained from a dynamic contrast-enhanced (DCE) permeability (T1) sequence were also unremarkable.
Images F-H are in the same level as D. After treatment for atypical mycobacteriosis, white matter changes disappeared, as shown in (FLAIR) images (i-l)
obtained two years after the initial exam (arrows in J and L point to biopsy sites, partially characterized in these images)
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Fig. 2 Brain biopsy results of a patient with reversible leukoencephalopathy. a to j: Brain biopsy results of the patient with reversible leukoencephalopathy
prior to atypical mycobacteria treatment shows (a) mild tissue rarefaction with vacuolation, very sparse perivascular inflammatory infiltrates, and (b) no
evidence of demyelination. c–d Presence of relatively few glial fibrillary acidic protein (GFAP) positive astrocytes with reduced aquaporin-4 expression in
the lesion compared to the surrounding area. Scale bar = 100 μm. High magnification (400x) on D shows aquaporin-4 on the membrane of reactive
astrocytes. Scale bar = 10 μm. e Aquaporin-1 expression is also reduced in the lesion, but in less extensively than aquaporin-4. f–g Myelin sheath is pre-
served with no loss of myelin basic protein (MBP) and myelin associated glycoprotein (MAG). h No signs of neuronal or axonal damage. i–j Few lympho-
cytes (CD45+) and macrophages (CD68+) are found in the perivascular space, while immunoglobulin and complement C9neo deposition are absent
(not shown). Scale bar = 50 μm. (Magnification a–d = 100x; e–j = 200x)
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studies suggest the pathogenic role of cellular channel
dysfunction. Reversible leukoencephalopathy has been
described in few anti-aquaporin-4 antibody positive neu-
romyelitis optica (NMO) cases following immunothera-
peutic interventions [3]. Lesion reversibility in these
cases suggests that immune-mediated tissue destruction
associated with blood–brain barrier (BBB) disruption
may not be the main underlying mechanism.
It is conceivable that vasogenic edema noted on
diffusion-weighted MRI sequences in reversible leukoence-
phalopathy cases represents parenchymal excess water
content, caused by impaired water influx control, inde-
pendent from BBB disruption. In our case, water influx
control was probably impaired due to astrocyte aquaporin
dysfunction, in a mechanism akin to that hypothesized in
brain edema associated with NMO [3]. Additionally,
experimentally induced acute hypertension in rabbits led
to exogenous markers leakage in arterioles and capillaries
through channels (often sigmoid-shaped) and cytoplasm
and by transendothelial pinocytosis, causing brain-barrier
disruption and edema [22]. These findings suggest im-
paired water channel function as a possible mechanism
underlying reversible leukoencephalopathy.
We are not aware of previous non-demyelinating re-
versible leukoencephalopathy cases that improved after
atypical mycobacteriosis treatment. We found vacuolated
white matter lesions with paucity of reactive astrogliosis
and decreased aquaporin water-channel expression. A
causal relationship between mycobacteriosis and intersti-
tial edema remains speculative. Alternatively, unexpected
drug effects may have contributed to brain changes reso-
lution. Elucidating pathogenic mechanisms underlying re-
versible leukoencephalopathies may lead to improved
therapeutic strategies to treat this condition.
Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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